Physician profile
Kevin Obi
NPI 1679062640
$10,697.05
in general payments reported to CMS, 2019-2025
15 companies · $5,251 in 2025
The $5,251 reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $509 · 2022: $361 · 2023: $1,611 · 2024: $2,966 · 2025: $5,251.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,641 · Education: $186.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,640.65 |
| Education | $186.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,865.22 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,766.38 | 2023-2025 | Caplyta |
| Abbvie INC. | $1,633.76 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,270.26 | 2024-2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $1,118.86 | 2022-2025 | Uzedy, Austedo Xr |
| Alkermes, INC. | $1,033.25 | 2023-2025 | Aristada, Lybalvi, Vivitrol |
| Neurocrine Biosciences, INC. | $648.39 | 2024-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $398.29 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $352.46 | 2025 | Fanapt, Hetlioz |
| Braeburn INC. | $285.25 | 2024-2025 | Brixadi |
| Indivior INC. | $142.17 | 2023-2025 | Perseris, Sublocade |
| Almatica Pharma LLC | $76.57 | 2025 | Loreev Xr |
| Supernus Pharmaceuticals, INC. | $47.15 | 2024 | Qelbree |
| Lundbeck LLC | $34.52 | 2025 | Abilify Asimtufii |
| Sunovion Pharmaceuticals INC. | $24.52 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Obi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.